AI-driven precision medicine for complex chronic diseases
The future of healthcare – creating better, more personalized diagnostic tools & treatment options
Personalized & predictive healthcare
Chronic diseases pose the greatest threat to global health. More personalized, predictive and preventative healthcare is the answer.
Mechanostics® are the solution – a new generation of diagnostic and prognostic tools to accurately identify the cause of disease and personalize interventions earlier than ever before.
Predict disease risk
Treat underlying causes
Prevent onset and progression
Improving outcomes, increasing healthspan, and reducing costs.
Successful & effective drug development
We maximize the probability of success and eliminate risk by making precision drug development possible in complex diseases.
Our mechanistic insights and stratification biomarkers enrich clinical trials and reveal the relationships between disease mechanisms, targets, treatments, and patients.
Developing the right treatments for the right patients, by understanding the biology that matters most.
Stratifying diseases at unmatched resolution
We achieve a unique mechanistic understanding of disease biology – identifying patient subgroups that are invisible to other analytical approaches, determining causality and enabling stratification at unprecedented resolution.
Our science holds the key to unlocking precision medicine for conditions beyond oncology – reducing the global burden of chronic diseases and improving health for billions of people.
This is precision medicine, for everyone.
Unique data access
Unparalleled access to multimodal patient data across chronic diseases, through partnerships with biobanks, disease charities, research consortia and global healthcare systems.
Combinatorial analytics
Science that goes far beyond the capabilities of any other AI or data model – generating 10x the signal from just 10% of the data and finding the biology that underpins disease.
Actionable insights
The deepest disease biology insights, mechanistic patient stratification, and biomarker discovery to identify risk and resilience factors and develop more effective diagnostics and treatments.
